Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omega Therapeutics Inc (NQ: OMGA )

0.9629 +0.0629 (+6.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,980
Open 0.9000
Bid (Size) 0.9500 (3)
Ask (Size) 0.9792 (4)
Prev. Close 0.9000
Today's Range 0.8950 - 0.9900
52wk Range 0.7500 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
From Omega Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
-67.58%
-67.58%
1 Month
-14.79%
-14.79%
3 Month
-21.07%
-21.07%
6 Month
-51.86%
-51.86%
1 Year
-56.03%
-56.03%

More News

Read More
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
From Omega Therapeutics
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Omega Therapeutics Through 4 Analysts
Via Benzinga
Expert Ratings For Omega Therapeutics
Via Benzinga
4 Analysts Have This To Say About Omega Therapeutics
Via Benzinga
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
From Omega Therapeutics
Via GlobeNewswire
Uber To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
How Is The Market Feeling About Omega Therapeutics?
Via Benzinga
OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
From Omega Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
From Omega Therapeutics
Via GlobeNewswire
OMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
From Omega Therapeutics
Via GlobeNewswire
OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
From Omega Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.